Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163251 | 0.82 | PRMT5 (0.58) | PRMT5MAP4K4DGAT2CKS1BSKP1 | |
| SCHEMBL18163226 | 0.81 | PRMT5 (0.56) | PRMT5MAP4K4DGAT2CKS1BSKP1 | |
| SCHEMBL6788585 | 0.76 | RET (0.55) | MAP4K4CKS1BSKP1SKP2GRIA1 | |
| SCHEMBL6528453 | 0.76 | PRMT5 (0.76) | PRMT5 | |
| SCHEMBL18163222 | 0.76 | MAP4K4 (0.52) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL18163277 | 0.76 | MAP4K4 (0.54) | PRMT5MAP4K4CKS1BSKP1SKP2 | |
| SCHEMBL30515303 | 0.75 | CKS1B (0.52) | MAP4K4CKS1BSKP1SKP2GRIA1 | |
| SCHEMBL6714931 | 0.74 | PRMT5 (0.56) | PRMT5MAP4K4DGAT2CKS1BSKP1 | |
| SCHEMBL10325481 | 0.74 | DGAT1 (0.62) | PRMT5 | |
| SCHEMBL30893577 | 0.73 | DDB1 (0.57) | MAP4K4CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | disclosed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | PRMT5 2217/4885MAP4K4 36/4885DGAT2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.